A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. - Wikidata - wikimedia - TriplyDB

A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.

A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.

http://www.wikidata.org/entity/Q34978590

about

Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria The influence of host genetics on erythrocytes and malaria infection: is there therapeutic potential?Malaria Parasites: The Great Escape Malaria vaccine clinical trials: what's on the horizon Plasmodium vivax Reticulocyte Binding Proteins Are Key Targets of Naturally Acquired Immunity in Young Papua New Guinean Children A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?P113 is a merozoite surface protein that binds the N terminus of Plasmodium falciparum RH5 Structural basis for inhibition of erythrocyte invasion by antibodies to Plasmodium falciparum protein CyRPA Plasmodium cynomolgi infections in rhesus macaques display clinical and parasitological features pertinent to modelling vivax malaria pathology and relapse infections Host-Parasite Interactions in Human Malaria: Clinical Implications of Basic Research Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization.Mastering malaria: what helps and what hurts.Network-based gene prediction for Plasmodium falciparum malaria towards genetics-based drug discovery.Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design Basigin is a druggable target for host-oriented antimalarial interventions.Characterization of Inhibitors and Monoclonal Antibodies That Modulate the Interaction between Plasmodium falciparum Adhesin PfRh4 with Its Erythrocyte Receptor Complement Receptor 1.Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".Recent advances in recombinant protein-based malaria vaccines.Structurally conserved erythrocyte-binding domain in Plasmodium provides a versatile scaffold for alternate receptor engagement.Designing malaria vaccines to circumvent antigen variability Generation of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01 Progress and prospects for blood-stage malaria vaccines Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity.Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines.The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria.Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection.One-step design of a stable variant of the malaria invasion protein RH5 for use as a vaccine immunogen.Host-parasite interactions that guide red blood cell invasion by malaria parasites.Recombinant modified vaccinia virus Ankara-based malaria vaccines.A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection Blood-stage malaria vaccines: post-genome strategies for the identification of novel vaccine candidates.Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag'.Non-human primate malaria parasites: out of the forest and into the laboratory.Malaria vaccines and human immune responses.Vaccines to Accelerate Malaria Elimination and Eventual Eradication.A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP142 in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage Challenge

P2860

Q24273364-F6163A49-A6F2-4E85-9C81-188C949A5DFE Q26700012-6C0F2149-FF47-49A4-AA51-49E0970E3786 Q26772878-7AD9B5CD-F0B9-4B8A-802D-92F5F734436C Q26799240-19480813-3830-4491-BE9B-451A59A1537B Q28080325-77C80B01-0EB1-45EC-8D6C-4BD23F47AD96 Q28083110-F950C40C-661C-4A4E-81DE-4E02D0DDC51D Q28554358-76724B6F-E0E2-4B3D-B928-1E983A792E3A Q29994671-2DB245FA-5971-4452-96AD-4B5A41018347 Q30042821-60669FE4-19EF-43B6-AE98-2DD375C79F4F Q30049152-034F4415-0E33-4A0A-8861-062332A98642 Q33435123-F907D7A4-8880-4CEA-B557-B4B887BC01A9 Q33701044-5C7AACCB-042F-4CA6-9E02-04CBD28E0B68 Q33798074-2B756835-1B8C-4B3A-AB40-6936F5257553 Q34509612-F3B050AA-3736-4876-B370-B72F81364EDA Q35189985-33D3FA2A-4FD7-4315-9CC0-BBACEA84506E Q35671066-ED6B03D3-D7AE-46B5-AF13-6584B95C80B3 Q35887367-51F71C58-CB42-46D4-A0CF-70772D5341D7 Q35894355-3BCA2D32-1A3A-44E6-8BD9-B4E7FB4B7419 Q36283289-D24D5CEE-86D9-4819-837B-E1065EB89F64 Q36394177-FEBC4523-BAF2-4EB4-993B-13D729D203EB Q36394182-62D8274D-5E4C-4F1F-B55A-C7FA72AC1FF4 Q36483323-E7626365-B9F9-4CBD-A776-4AF49D782D4A Q36514853-732BC5B8-7E0E-400B-8779-4264532BCD01 Q36687352-4D3BD911-68E8-4193-A6D4-F0FCD1B7469D Q36871970-321E81FE-E6F2-438A-9CEF-18A3F7AE19AB Q37025030-6C2D8E0D-4737-460B-9ED9-CC223A6EDD6B Q37129892-405989E2-DDE5-45CE-A9C0-62B7909DFD93 Q37153663-21F6FCF3-E077-4BBB-9E85-841D01C6AA8A Q37239883-103C884F-707F-4DC8-B7D1-0315EDEDAEAD Q37334935-227909AB-6E63-43B0-AFA9-F4B3F7E22E17 Q37626240-66A1B60A-B1FD-41EA-BCB0-CE3AFCCC49EE Q38376500-88480715-168C-4F40-B269-4F7C43FBA5E8 Q38618898-98B0838B-0CA7-4F77-913D-1A14D32E8944 Q38626558-3993D46B-85C5-4C0C-BBFE-A653557C6699 Q38672088-93AA4E8E-EBC9-449F-B719-7A786E11DA79 Q38718229-1828786D-C860-4F6C-99AA-243462EC9849 Q38810886-E21A53F6-D909-4B6C-A2E4-4C800B568A9C Q38854831-D41ED9B0-1228-404D-928C-9EDCC5EC54DF Q39296506-9D7ADDEC-C45B-4485-AAF5-BC5624B5F090 Q39315273-C5080B65-7AF3-4CC1-A00A-1A78A65B83EB

P2860

A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.

http://www.wikidata.org/entity/Q34978590

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

A PfRH5-based vaccine is effic ...... um infection in aotus monkeys.

@ast

A PfRH5-based vaccine is effic ...... um infection in aotus monkeys.

@en

A PfRH5-based vaccine is effic ...... um infection in aotus monkeys.

@nl

type

label

A PfRH5-based vaccine is effic ...... um infection in aotus monkeys.

@ast

A PfRH5-based vaccine is effic ...... um infection in aotus monkeys.

@en

A PfRH5-based vaccine is effic ...... um infection in aotus monkeys.

@nl

prefLabel

A PfRH5-based vaccine is effic ...... um infection in aotus monkeys.

@ast

A PfRH5-based vaccine is effic ...... um infection in aotus monkeys.

@en

A PfRH5-based vaccine is effic ...... um infection in aotus monkeys.

@nl

P1433

Q34978590-9A01C055-230D-4B5D-B9CB-93D2A6A98A9E

P1476

Q34978590-DB0270FE-CA7F-4F8D-9F5C-DE7E307FC403

P2093

Q34978590-05A14463-9A14-4BAD-8D8C-EBF2E43CB849

Q34978590-3AF694D7-B76C-4CCE-9852-82F916B64506

Q34978590-5B0687FA-EF83-40A7-9951-2E25FB0D6058

Q34978590-5E6E806C-9732-4C90-A97E-6409091D7472

Q34978590-5F9EB161-6C87-4761-8787-6C7A7820BC4D

Q34978590-6A9D8F17-0D27-4C84-A4ED-5FDF1D36006E

Q34978590-7BD7A236-EEB3-4969-A732-FF31202AB698

Q34978590-7C092DB0-D6C8-4835-BFB8-7764BA798B75

Q34978590-8E2A7AF2-B697-4BF7-8C3F-281BA4FD2DF5

Q34978590-9D71D854-4213-4C97-9DDD-2C8006D49249

P2860

Q34978590-02996F7A-A7EA-4727-9FDD-FD77C067E3F0

Q34978590-046CB1B2-723D-44FF-92E7-1BEC6384FDDF

Q34978590-064D1277-4DCD-4958-92DE-34EA5D786294

Q34978590-1012060D-AA0A-44DF-83C5-069D0195F30C

Q34978590-15197937-AF8F-4564-918F-874AAC7E7BA0

Q34978590-177E71DD-F776-4379-857D-1545FD714499

Q34978590-17F7949A-C83B-41F0-9698-085E3EC6888D

Q34978590-1CA03D89-09AF-44B1-B838-2689822C27A5

Q34978590-20E02296-EB0E-4649-A67F-F4A7955B2A92

Q34978590-2467980A-6763-42D5-ADA2-D8FECAC3AFE8

P304

Q34978590-C50E7B88-6B16-4689-9027-37410F7BE5DE

P31

Q34978590-5AA2E13C-CB15-40D2-B0C6-ACF320221510

P356

Q34978590-A640D817-748D-45A6-B697-C39E00B08274

P433

Q34978590-5FF61036-B009-4DB8-95BA-764DBEF6F192

P478

Q34978590-C5A0623B-FD73-411A-A1A4-7CDF2D0611EA

P50

Q34978590-47A55D24-E606-4B8D-9ADE-6D30E522A3B4

Q34978590-6B4AF63D-48F1-4FCE-868A-543088E76942

Q34978590-7EBDD98B-8651-44DE-A901-61578884DE0E

Q34978590-AED97CAC-0A86-414A-A4D6-FFFB94AB7336

Q34978590-D4BBE196-64A6-4668-9EF0-90664BFEAD91

Q34978590-E502FF2D-3FD0-42D6-B0DF-7DF70AE510A9

Q34978590-FF68AB08-3ED0-477E-8886-161104E520F8

P577

Q34978590-049D12DB-BE0A-4872-A453-158E00B17F1D

P5875

Q34978590-1B6A1A6C-3624-4762-A087-E1A3E31211C4

P698

Q34978590-8CEC52E6-B615-45A5-B9C3-EB4CFFB12818

P921

Q34978590-605B99D4-C3AD-4909-92F1-100804117AF8

Q34978590-CF9B47AF-E9F8-4B81-83EE-54207AAED44E

P932

Q34978590-3960EAF1-511C-47B6-BD25-129C81B91027

P356

J.CHOM.2014.11.017

P1433

Cell Host & Microbe

P1476

A PfRH5-based vaccine is effic ...... um infection in aotus monkeys.

@en

P2093

Ababacar Diouf

http://www.w3.org/2001/XMLSchema#string

Alison V Turner

http://www.w3.org/2001/XMLSchema#string

Andrés G Lescano

http://www.w3.org/2001/XMLSchema#string

Carmen M Lucas

http://www.w3.org/2001/XMLSchema#string

Cécile Crosnier

http://www.w3.org/2001/XMLSchema#string

Daniel G W Alanine

http://www.w3.org/2001/XMLSchema#string

G Christian Baldeviano

http://www.w3.org/2001/XMLSchema#string

Jeromy T Moorhead

http://www.w3.org/2001/XMLSchema#string

Joseph J Illingworth

http://www.w3.org/2001/XMLSchema#string

Karina P Leiva

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccines against malaria

Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing

Global malaria mortality between 1980 and 2010: a systematic analysis

Immune mechanisms in malaria: new insights in vaccine development

Plasmodium falciparum erythrocyte invasion: combining function with immune evasion

Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum

High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells

Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection

Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques

Immunity to non-cerebral severe malaria is acquired after one or two infections

P304

130-139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CHOM.2014.11.017

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Alexandra Spencer

Simon J. Draper

Alexander D Douglas

Gavin J. Wright

Julio A Ventocilla

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270969020

http://www.w3.org/2001/XMLSchema#string

P698

25590760

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium falciparum

reticulocyte binding protein homologue 5

P932

4297294

http://www.w3.org/2001/XMLSchema#string